Clinical Trial Update: BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating daclatasvir in combination with peg-interferon alfa-2a and ribavirin in treatment-naive patients with Hepatitis C; the study c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daclatasvir (daclatasvir)
• Pegylated interferon alfa-2a (Peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2015-09-16